Hepatitis C: Boehringer Ingelheim's faldaprevir granted accelerated...

"The acceptance for accelerated assessment by the EMA supports our position that if approved, faldaprevir* will provide an important alternative to currently available hepatitis C treatments."

http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20131125005954&newsLang=en&ndmConfigId=1000639&vnsId=41